Black Diamond Therapeutics, Inc. - Common Stock, par value $0.0001 per share (BDTX) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2020 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
BDTX on Nasdaq
Shares outstanding
58,000,000
Price per share
$2.49
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
16,641,030
Total reported value
$40,433,027
% of total 13F portfolios
0%
Share change
+3,864,785
Value change
+$9,231,172
Number of holders
61
Price from insider filings
$2.49
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Black Diamond Therapeutics, Inc. - Common Stock, par value $0.0001 per share (BDTX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BB BIOTECH AG 4.8% -69% $4,373,675 -$9,254,867 2,733,547 -68% BB Biotech AG 19 Mar 2025
BlackRock, Inc. 4.5% $4,037,634 2,523,521 BlackRock, Inc. 31 Mar 2025
Vestal Point Capital, LP 1.5% $2,166,300 870,000 Vestal Point Capital, LP 31 Dec 2025

As of 31 Dec 2025, 61 institutional investors reported holding 16,641,030 shares of Black Diamond Therapeutics, Inc. - Common Stock, par value $0.0001 per share (BDTX). This represents 29% of the company’s total 58,000,000 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Black Diamond Therapeutics, Inc. - Common Stock, par value $0.0001 per share (BDTX) together control 34% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
T. Rowe Price Investment Management, Inc. 4% 2,332,222 -78% 0.01% $5,668,000
VANGUARD GROUP INC 3.8% 2,188,857 0% 0% $5,318,922
ACADIAN ASSET MANAGEMENT LLC 2.8% 1,630,173 +239% 0.01% $3,956,000
MARSHALL WACE, LLP 1.9% 1,110,088 -15% 0% $2,697,515
Siren, L.L.C. 1.8% 1,046,517 0% 0.08% $2,543,036
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 1.8% 1,040,468 +16% 0% $2,528,337
JANE STREET GROUP, LLC 1.7% 961,776 +305% 0% $2,337,115
RENAISSANCE TECHNOLOGIES LLC 1.6% 949,735 +58% 0% $2,307,856
BlackRock, Inc. 1.5% 888,260 -14% 0% $2,158,472
Vestal Point Capital, LP 1.5% 870,000 -84% 0.08% $2,114,100
DIMENSIONAL FUND ADVISORS LP 1.5% 857,015 +88% 0% $2,082,832
D. E. Shaw & Co., Inc. 1.1% 655,772 +357% 0% $1,593,526
Connor, Clark & Lunn Investment Management Ltd. 1.1% 654,699 +397% 0% $1,590,919
AWM Investment Company, Inc. 1.1% 625,000 +4.2% 0.15% $1,518,750
FMR LLC 0.93% 541,154 +19% 0% $1,315,005
GEODE CAPITAL MANAGEMENT, LLC 0.87% 505,780 +1.1% 0% $1,229,422
NORTHERN TRUST CORP 0.82% 472,702 -3.1% 0% $1,148,666
CITADEL ADVISORS LLC 0.73% 425,459 0% $1,033,865
WINTON GROUP Ltd 0.73% 421,280 0.04% $1,023,710
O'SHAUGHNESSY ASSET MANAGEMENT, LLC 0.61% 354,454 +149% 0% $861,323
GOLDMAN SACHS GROUP INC 0.56% 325,327 -28% 0% $790,545
GLOBEFLEX CAPITAL L P 0.53% 305,276 0% 0.11% $741,821
MILLENNIUM MANAGEMENT LLC 0.51% 296,556 -65% 0% $720,631
STIFEL FINANCIAL CORP 0.47% 274,995 +24% 0% $668,240
UBS Group AG 0.44% 257,633 -59% 0% $626,048

Institutional Holders of Black Diamond Therapeutics, Inc. - Common Stock, par value $0.0001 per share (BDTX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 16,641,030 $40,433,027 +$9,231,172 $2.43 61
2025 Q3 38,780,810 $146,973,938 +$5,639,493 $3.79 89
2025 Q2 38,616,493 $95,766,554 -$4,378,949 $2.48 92
2025 Q1 40,656,241 $63,017,852 -$11,756,469 $1.55 83
2024 Q4 47,903,925 $102,516,125 -$13,785,684 $2.14 85
2024 Q3 48,717,118 $211,892,256 +$1,570,817 $4.35 95
2024 Q2 46,760,739 $217,913,327 +$31,657,196 $4.66 88
2024 Q1 39,430,252 $199,910,697 +$10,671,909 $5.07 86
2023 Q4 38,119,952 $107,120,051 +$4,413,540 $2.81 73
2023 Q3 37,180,210 $106,709,201 -$21,943,325 $2.87 71
2023 Q2 41,421,828 $209,176,335 +$105,453,106 $5.05 72
2023 Q1 21,491,972 $40,617,428 +$846,555 $1.89 47
2022 Q4 21,053,167 $37,894,305 -$721,593 $1.80 56
2022 Q3 21,487,475 $36,340,473 -$284,945 $1.69 57
2022 Q2 21,498,645 $52,895,689 -$3,549,739 $2.46 56
2022 Q1 22,887,182 $64,088,307 -$2,429,770 $2.77 69
2021 Q4 23,198,177 $123,630,624 -$12,989,218 $5.33 83
2021 Q3 24,374,413 $206,301,397 -$11,175,534 $8.46 89
2021 Q2 25,397,669 $309,589,838 -$81,437,251 $12.19 97
2021 Q1 29,083,953 $705,520,847 -$7,557,586 $24.26 109
2020 Q4 28,616,097 $917,170,806 +$140,401,559 $32.05 109
2020 Q3 23,764,080 $718,480,421 +$753,590 $30.23 88
2020 Q2 22,835,597 $959,367,654 +$39,864,306 $42.16 79
2020 Q1 22,285,008 $555,219,061 +$555,219,061 $24.95 65